4.4 Article

Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder

期刊

JOURNAL OF ANXIETY DISORDERS
卷 22, 期 2, 页码 310-318

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.janxdis.2007.03.001

关键词

social anxiety disorder; dual-diagnosis; comorbidity; SSRI

资金

  1. NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013379, K23AA014430, K24AA013314, P50AA010761] Funding Source: NIH RePORTER
  2. NIAAA NIH HHS [K24 AA013314, K23 AA014430-04, K23 AA014430, R01 AA013379, K23 AA014430-01, K23 AA014430-02, P50 AA010761, K23 AA014430-03] Funding Source: Medline

向作者/读者索取更多资源

Patients with social anxiety disorder who are seen in clinical practice commonly have additional psychiatric comorbidity, including alcohol use disorders. The first line treatment for social anxiety disorder is selective-serotonin-reuptake-inhibitors (SSRIs), such as paroxetine. However, the efficacy of SSRIs has been determined with studies that excluded alcoholics. Forty two subjects with social anxiety and a co-occurring alcohol use disorder participated in a 16-week, double-blind, placebo-controlled clinical trial to determine the efficacy of paroxetine for social anxiety in patients with co-occurring alcohol problems. Paroxetine was superior to placebo in reducing social anxiety, as measured by the Liebowitz Social Anxiety Scale total and subscale scores and additional measures of social anxiety. This study provides the first evidence-based recommendation for the use of an SSRI to treat social anxiety in this patient population. (C) 2007 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据